Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Visiongain publishes Global Biosimilars and Follow-On Biologics Market 2020-2030 report

This image opens in the lightbox

News provided by

Visiongain

26 Aug, 2020, 11:00 GMT

Share this article

Share toX

Share this article

Share toX

Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietin's, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones, Blood Disorders, Growth Hormone Deficiency, Autoimmune Diseases, Cancer, Diabetes, Infectious Diseases

LONDON, Aug. 26, 2020 /PRNewswire/ -- The global biosimilars and follow-on biologics market is estimated to have reached $19.87bn in 2019 and expected to grow at a CAGR of 7.1% in the first half of the forecast period. The market is dominated by Biosimilar Monoclonal Antibodies, this submarket is estimated to hold 36.5% share of this market in 2020.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 420-page report you will receive 131 tables and 90 figures– all unavailable elsewhere.

The 420-page Visiongain report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please email contactus@visiongain.com or refer to our website: https://www.visiongain.com/report/global-biosimilars-and-follow-on-biologics-market-2020-2030/#download_sampe_div

Report Scope

• Global Biosimilars and Follow-on Biologics Market forecasts from 2020-2030

• Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2029 for 8 individual therapeutic submarkets:

• Monoclonal antibodies (mAbs)

• Fusion proteins

• Insulin

• Erythropoietin (EPO)

• Granulocyte colony-stimulating factor (G-CSF)

• Interferons

• Growth hormones

• Fertility hormones

• This report also shows revenue to 2030 for 11 individual submarkets within the above segments:

• Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab

• Human insulin, insulin analogues, insulin glargine and insulin lispro

• Interferon alfa and interferon beta

• Our analyses show individual revenue forecasts to 2030 for 17 national markets:

• US

• Canada

• Japan

• Germany

• France

• UK

• Italy

• Spain

• Sweden

• Norway

• China

• India

• South Korea

• Russia

• Brazil

• South Africa

• Australia

• Our study discusses the leading companies that are involved in the biosimilars and follow-on biologics industry:

• Amgen Inc

• Biocon Limited

• Celltrion Healthcare Co. Ltd

• Dong-A Socio Holdings Co. Ltd

• Dr.Reddy's Labs (DRL)

• & Other Companies

• Our study provides a SWOT analysis of the biosimilars and follow-on biologics market.

• Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market, including these influences:

• Strategies for developing biosimilars – needs, demand, challenges and opportunities

• Guidelines from regulators (FDA, EMA and others)

• Patent challenges and data exclusivity for biopharmaceuticals

• Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals

• Developments in technology and operations for biosimilar drug production.

To request a report overview of this report please email contactus@visiongain.com or refer to our website: https://www.visiongain.com/report/global-biosimilars-and-follow-on-biologics-market-2020-2030/

Did you know that we also offer a report add-on service? Email contactus@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

Amgen Inc.

Biocon Limited

Bio-Manguinhos

Bionovis

BioXpress Therapeutics

Boehringer Ingelheim

Bristol-Myers Squibb

Cell Therapeutics

Celltrion Healthcare Co. Ltd.

Dong-A Socio Holdings

Dr. Reddy's Laboratories Ltd.

Emcure

EMS

Epirus Biopharmaceuticals

Farmasa

Fresenius

Fujifilm Kyowa Kirin Biologics

F Hoffmann-La Roche Ltd.

Gedeon Richter Plc

GENEXINE INC.

Hanwha Chemical

Harvest Moon

Hospira

Hypermarcas

iBio

IBSS Biomed

ImClone LLC

Instituto Vital Brazil

IPCA Labs

Isu Abxis

Janssen

Johnson & Johnson

Kyowa Hakko Kirin

Laboratorios Liomont

Intas Pharmaceuticals

LG Life Sciences

MABXIENCE S.A.

Merck Serono

Millhouse LLC

Mitsubishi Tanabe

Mochida Pharmaceutical

Mustafa Nevzat Pharmaceuticals

Natco Pharma

Nichi-Iko Pharmaceutical Co.

Mylan N.V.

Nippon Kayaku Co. Ltd.

Pfizer Inc.

QuantiaMD

Quintiles

Reliance Life Sciences

Roche

Samsung Bioepis

Sandoz

Sanofi

Schnell

Seattle Genetics

Shanghai CP Guojian

Shionogi

Sorrento

Spectrum Pharmaceuticals

Stada Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

UCB

União Química

Viropr

Walvax Biotechnology

Wyeth

Zenotech

Zhejiang Huahai Pharmaceutical

Wockhardt Limited

Zydus Cadila group

List of Organizations Mentioned in the Report

Agence française de sécurité sanitaire des produits de santé (ANSM)

Agência Nacional de Vigilância Sanitária (ANVISA)

Chinese Centre for Drug Evaluation (CDE)

Cour des Comptes (France)

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)

Fraunhofer Center for Molecular Biology

Health Canada

India Brand Equity Foundation

Korean Food and Drug Administration (KFDA)

Medicines and Healthcare Products Regulatory Agency (MHRA)

Ministry of Food and Drug Safety (South Korea)

Ministry of Health (Russia)

Ministry of Health, Labour and Welfare (MHLW)

National Institute for Health and Care Excellence (NICE)

National Institute for Health Research Horizon Scanning Centre

Norwegian Medical Agency

Russian Ministry of Health

Scientific Centre for Expertise of Medicinal Application Products (Russia)

Spanish Ministry of Health

State Food and Drug Administration (SFDA)

The Cancer Centre Bahamas

Washington Legal Foundation

World Health Organization (WHO)

To see a report overview please e-mail contactus@visiongain.com

RELATED REPORTS:

Global Biosimilar Monoclonal Antibodies Forecast 2020-2030

Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029

Global Bioreactors Market 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.